Skip to main content
SpringerLink
Log in

Immunothérapie et dysfonctions thyroïdiennes : mise au point sur les connaissances actuelles

Immunotherapy and thyroid dysfunction: an update on current understanding

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Les nouvelles immunothérapies constituent une avancée dans la prise en charge du mélanome, du cancer pulmonaire et d’autres cancers. Le profil de tolérance de ces traitements est nouveau par rapport aux antinéoplasiques. Parmi ces effets secondaires, les dysfonctions thyroïdiennes sont particulièrement fréquentes. Il convient donc d’en connaître les signes cliniques qui doivent amener à leur diagnostic, et ce en fonction de chaque molécule, ainsi que les modalités de leur prise en charge.

Abstract

Immunotherapy is a revolution in the treatmant of melanoma, lung cancer, and some other cancers. Tolerance of these treatments is new. Among the toxicities related to the treatment, thyroid dysfunction is also possible. It is necessary to know how to diagnose and manage them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF (1998) The endocrine effects of nonhormonal antineoplastic therapy. Endocrin Rev 19:144–72

    Article  CAS  Google Scholar 

  2. Ryder M, Callahan M, Postow MA, et al (2014) Endocrinerelated adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21:371–81

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tome M, Chami R, Petrosians P, et al (2012) Le dysfonctionnement thyroïdien, interrelation génétique–environnement. Rev Med Liège 67:314–18

    CAS  PubMed  Google Scholar 

  4. Recommandations HAS avril 2007. www.sfendocrino.org>article>-thyroide

  5. Hamnvik OPR, Reed Larsen P, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Razvi S, Ingoe L, Keeka G, et al (2007) The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 92:1715–23

    Article  CAS  PubMed  Google Scholar 

  7. Karmisholt J, Andersen S, Laurberg P (2011) Variation in thyroid function in subclinical hypothyroidism: importance of clinical follow-up and therapy. Eur J Endocrinol 164:317–23

    Article  CAS  PubMed  Google Scholar 

  8. Diez JJ, Iglesias P (2004) Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab 89:4890–7

    Article  CAS  PubMed  Google Scholar 

  9. Hamnvik OPR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schwartzentruber DJ, White DE, Zweig MH, et al (1991) Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 68:2384–90

    Article  CAS  PubMed  Google Scholar 

  11. Daud A (2015) Current and emerging perspectives on immunotherapy for melanoma. Semin Oncol 42:S3–S11

    Article  CAS  PubMed  Google Scholar 

  12. Blansfield JA, Beck KE, Tran K, et al (2005) Cytotoxic Tlymphocyte- associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Robert C, Thomas L, Bondarenko I, et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–26

    Article  CAS  PubMed  Google Scholar 

  14. Kirkwood JM, Lorigan P, Hersey P, et al (2010) Phase 2 trial of tremelimumab in patients with advanced refractiry of relapsed melanoma. Clin Cancer Res 16:1042–8

    Article  CAS  PubMed  Google Scholar 

  15. Di Giacomo AM, Danielli R, Calabrò L, et al (2011) Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 60:467–77

    Article  CAS  PubMed  Google Scholar 

  16. Hod FS, O’Day SJ, McDermott DF, et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–23

    Article  CAS  Google Scholar 

  17. Weber JS, D’Angelo SP, Minor D, et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment: a randomised, controlled, openlabel phase 3 trial. Lancet Oncol 16:375–84

    Article  CAS  PubMed  Google Scholar 

  18. Brahmer JR, Tykodi SS, Chow LQM, et al (2012) Safety and activity of anti-PD-1 antibody in patients with advanced cancer. N Engl J Med 366:2455–65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Robert C, Joshua AM, Kefford R, et al (2015) Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001 — ASCO Annual Meeting. J Clin Oncol 33l: 9050 (May 20 supplement)

    Google Scholar 

  20. Robert C, Schachter J, Long GV, et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–32

    Article  CAS  PubMed  Google Scholar 

  21. Postow MA, Chesney J, Pavlick AC, et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–17

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Mutualiste Montsouris, service d’oncologie médicale du Pr Louvet, 42, bd Jourdan, F-75014, Paris, France

    T. Lambert

  2. APHP, hôpital Saint-Louis, 1 Avenue Claude-Vellefaux, F-75010, Paris, France

    L. Doucet

Authors
  1. T. Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Doucet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Lambert.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lambert, T., Doucet, L. Immunothérapie et dysfonctions thyroïdiennes : mise au point sur les connaissances actuelles. Oncologie 18, 509–515 (2016). https://doi.org/10.1007/s10269-016-2659-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-016-2659-8

Mots clés

Keywords

Search

Navigation